1. Monoclonal Antibodies in CVD: What Does the Future Hold?

2. Goals

3. Monoclonal Antibodies: The Basics

4. Study of Monoclonal Antibodies in CVD

5. Gain-of-Function vs Loss-of-Function Mutations in PCSK9

6. The ARIC Study

7. Mechanism of Action

8. Phase 2 Trial of AMG 145 in Patients With Hypercholesterolemia

9. Phase 2 Trial of AMG 145: Selected Results

10. Phase 2 Trial of REGN727/SAR236553 in Patients With Hypercholesterolemia

11. Phase 2 Trial of REGN727/SAR236553: Selected Findings

12. Statin Intolerance

13. AEs in a Phase 2 Trial of AMG 145

14. AEs in a Phase 2 Trial of AMG 145 (cont)

15. AEs in a Phase 2 Trial of REGN727/ SAR236553

16. AEs in a Phase 2 Trial of REGN727/ SAR236553 (cont)

17. Potential Therapeutic Roles for PCSK9 Monoclonal Antibodies

18. Phase 3 Trials: ODYSSEY Outcomes

19. Phase 3 Trials: FOURIER Outcomes

20. The Effects on Lipoprotein(a)

21. Abbreviations

22. Abbreviations (cont)

23. References

24. References (cont)

25. References (cont)